Implementing rigorous assessments and securing the highest quality of data are major goals in dermatology clinical research. Traditional clinical trials can make it hard for patients to participate for reasons such as a busy work or personal life or the potential patient living far from a study site.
Decentralized clinical trials can open opportunities for wider inclusion and diversity within the dermatology patient populations, which is increasingly important as competition for patients for dermatology trials is fierce with many new drugs in development. By reducing barriers to clinical trial access including time commitment and location, decentralized trials can boost enrollment and increase retention and study compliance.
However, trial processes including multiple assessments that are key to capturing efficacy endpoints in these trials still require the same level of rigor as a centralized approach. With these assessments focused largely on raters and patients’ visual interpretation, how do we solve the challenge of these assessments when they are done remotely?
This webinar will identify key points to consider when designing and planning decentralized dermatology clinical trials, including:
- Strategies to result in favorable outcomes from a time, cost, and data quality perspective
- Study protocol considerations
- Recruitment metrics comparison: traditional clinical trials versus DCT
- Hybrid clinical trials versus complete DCT models
- Virtual options fit for purpose in dermatology trials
And we’ll discuss reporting technologies such as:
- Photography — at-home and on-site options
- Electronic diaries
- Wearable biomarker devices
- Telemedicine
Key Learning Objectives
- Strategies to reduce the patient burden of participating in a trial, increase patient engagement, and support patient in the data capture as we continue to add new technologies
- Study protocol considerations
- Recruitment metrics comparison: traditional clinical trials versus DCT
- Hybrid clinical trials versus complete DCT models
- Virtual options fit for purpose in dermatology trials
Target Audience
- C-Suite
- SVP & VP
- President
- Exec Director
- Director
- Heads of R&D
- Dermatology companies
- Small to mid-sized Pharma and biotech companies